Over 150 established PDX models across 20+ cancer types
Accelerate Your Path to Effective Cancer Therapies with GD3
Powering Precision Oncology with Patient-Centered Models
At GD3, we help cancer researchers and drug developers go further, faster—with highly predictive patient-derived xenograft (PDX), CDX, syngeneic, and ex vivo models that mirror the complexity of real tumors. Our preclinical platforms deliver actionable insights to support the development of safer, more effective cancer treatments.
Get answers that move your research forward faster, with more confidence.
Why Leading Biopharma Teams Choose GD3
Over 90 extensively validated human cancer cell lines with comprehensive clinical/genomic data
Over 40 mouse and rat syngeneic cancer cell lines
Over 45 GFP-Luc labeled cell lines for orthotopic, disseminating and metastasis studies
Advanced genomic profiling to guide ADC and CAR-T programs
Efficient model selection via our intuitive online database
Custom development options tailored to your target profile
Fast-Track Efficacy with Our PDX Discovery Platform
Our PDX models are engineered for translational relevance, retaining the key molecular and pharmacologic traits of patient tumors. Most models are thoroughly profiled using:
mRNA sequencing and IHC validation
Gene expression correlation to drug response
Orthogonal quantitative methods for high reproducibility
Gain earlier confidence in how your therapies might perform in real patients.
Deeply Characterized Models for Oncology Innovation
Patient-Derived Xenografts (PDX)
Clinically relevant, predictive tumor behavior. Reliable data.
More than 60 proprietary PDX-derived cell lines
Validated across a broad spectrum of indications (lung, breast, colon, ovarian, prostate, etc.)
Includes hard-to-treat models with mutations in KRAS, BRCA2, ATM, PTEN, and more
Biomarker-positive subsets for HER2, TROP-2, Claudin-18.2, B7-H3/4, c-Met
Access GD3’s comprehensive preclinical cancer model collection via our user-friendly database. Search by:
Tumor type or origin
Cancer subtype
Genomic mutation
Model system (PDX, CDX, syngeneic)
Prior treatment history
Cell Line-Derived Xenografts (CDX)
Widely used, well-characterized, and efficient murine syngeneic and human-derived cell line models.
Robust models for high-throughput screening
Orthotopic and subcutaneous tumor models
Metastatic and disseminated cancer models
Can be implemented after in vitro cell line sensitivity is determined
Ideal for complementing PDX studies
Ex Vivo Culture Systems
Closer to the tumor microenvironment.
Advanced 2D/3D cell culture systems
Ex vivo co-culture assays
Study drug resistance, combination effects, and tumor-stroma interactions
Optimize compound selection with rapid, reproducible testing
Screen multiple compound analogues to select potent anti-cancer therapeutics
Perform combination studies to elucidate synergistic, additive or antagonistic nature of the treatments
Accelerate the development of novel cancer therapies
Designed for Targeted Therapies and Precision Medicine
We support programs focused on ADC, CAR-T, and immune-oncology agents through:
Expression profiling of 60+ therapeutic targets
IHC validation and gene expression mapping
Tools to define patient selection biomarkers, understand resistance, and refine combinations
Ask us about IHC Profiling of your target of interest